LEPU SCIENTECH MEDICAL TECHNOLOGY (SHANGHAI) CO., LTD.*

樂普心泰醫療科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2291)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

The Board is pleased to announce the unaudited consolidated financial results of the Group for the six months ended June 30, 2026, together with the comparative figures for the six months ended June 30, 2025 as below.

The interim results of the Group for the six months ended June 30, 2026 have been reviewed by the Audit Committee and by BDO China Shu Lun Pan Certified Public Accountants LLP, the independent auditor of the Group, in accordance with the China Certified Public Accountant Review Standard No. 2101 "Review of interim financial information performed by the independent auditor of the entity" issued by the Chinese Institute of Certified Public Accountants.

FINANCIAL HIGHLIGHTS

– Revenue decreased by 5.9% from RMB329.7 million for the six months ended June 30, 2025 to RMB310.1 million for the six months ended June 30, 2026.

– Gross profit decreased by 10.5% from RMB284.3 million for the six months ended June 30, 2025 to RMB254.5 million for the six months ended June 30, 2026.

– Research and development expenses decreased by 22.9% from RMB25.4 million for the six months ended June 30, 2025 to RMB19.5 million for the six months ended June 30, 2026.

– Net profit attributable to shareholders of the parent company decreased by 19.5% from RMB182.0 million for the six months ended June 30, 2025 to RMB146.5 million for the six months ended June 30, 2026.

– The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2026 (six months ended June 30, 2025: nil).

Note:

Certain amounts and percentage figures included in this announcement have been subject to rounding. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures preceding them. Any discrepancies in any table or chart between the total shown and the sum of the amounts listed are due to rounding.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

For many years, the Group has focused on the research and development, production, and commercialization of interventional medical devices for structural heart disease and pan-cardiovascular diseases. After more than 20 years of deep engagement in the industry, the Group has established a profound technological accumulation and market foundation in the field of traditional metal occluders. In recent years, the Group has successfully applied biodegradable materials to interventional devices for structural heart disease and is one of the first enterprises globally to commercialize biodegradable occluders. Many of its products are the world's first of their kind to be approved for marketing, playing a significant leading role in the industry's technological iteration. At the same time, the Group continues to expand into other sub-fields of structural heart disease, such as heart valves and mechanical circulatory support, as well as into pan-cardiovascular fields, such as the aorta and peripheral vessels, thereby achieving both vertical extension and horizontal deployment based on its core technology platform.

The Group's existing product pipeline covers two major areas, structural heart disease and peripheral vascular disease, with a total of six product pipelines. Among these, congenital heart disease, cardioembolic stroke prevention, interventional valves and interventional heart failure belong to the structural heart disease field, which is the strategic focus of the Group's core business; aortic and peripheral products belong to the peripheral vascular field, representing a natural extension of the Group based on its two major technology platforms of nitinol braiding and biodegradable materials; and pathway products provide supporting assistance for surgeries across various pipelines. The six product pipelines are mutually synergistic, collectively forming the Group's capabilities for providing end-to-end solutions, from diagnostic screening and intraoperative support to implant treatment.

In the fields of congenital heart defect occluders and cardioembolic stroke prevention, the Group, with metal occluders as its cornerstone and biodegradable occluders as its core competitive strength, continues to lead technological iteration and market penetration. In the field of interventional heart valves, it is steadily advancing commercialization and internationalization with a differentiated product portfolio. In emerging fields such as interventional heart failure, aortic and peripheral interventions, the Group has multiple products entering the clinical trial stage, reserving new momentum for future business growth. The Group will continue to enrich its product portfolio from both breadth and depth dimensions, consolidating and expanding its market position in the field of structural heart disease and peripheral vascular interventional devices.

As of the date of this announcement, the Group owns a total of 32 marketed products (including occluders, heart valves, and accessories), with another 3 products in the registration review or preparation stage, and 27 products in different research and development stages.

Progress of core products in each product pipeline over the next 5 years

Project Stage/Time	2026	2027	2028	2029	2030
Registration and Approval	Approval of MemoCarna® Oxide Coating PFO Occluder	Approval of Bio-Lefort® Biodegradable LAA Occluder	Submission of NMPA registration application for Aortic Embolisation Occluder	Submission of NMPA registration application for Biodegradable Aortic Occluder	Submission of NMPA registration application for Biodegradable Aortic Embolisation Occluder
	Submission of NMPA registration application for Bio-Lefort® Biodegradable LAA Occluder	Approval of Vascular Closure System	Submission of NMPA registration application for MemoClip-A® Transapical Mitral Valve Clip Repair System	Submission of NMPA registration application for Dense Mesh Left Atrial Appendage Occluder	Submission of NMPA registration application for ScienMelon® Polymeric Leaflet Valve
	Submission of NMPA registration application for Vascular Closure System			Submission of NMPA registration application for Transcatheter Aortic Valve System (TAVR for regurgitation indication)	Submission of NMPA registration application for ScienChute® Aortic Valve Stenosis Treatment System
				Submission of NMPA registration application for Interventional Left Ventricular Assist Device	Submission of NMPA registration application for MemoChord® Mitral Valve Repair System
					Submission of NMPA registration application for MemoClip-F® Transfemoral Mitral Valve Clip Repair System
					Submission of NMPA registration application for Transcatheter Mitral Valve Replacement System
					Submission of NMPA registration application for Implantable Ventricular Assist System
					Submission of NMPA registration application for Atrial Shunt Device I
Clinical Trials	Completion of enrollment for Aortic Embolisation Occluder	Completion of enrollment and follow-up for Transapical Mitral Valve Clip Repair System	Entry into clinical trials for Aortic Dissection Occluder		
	Entry into clinical trials for Biodegradable Vascular Plug	Completion of clinical enrollment for Biodegradable Aortic Occluder	Entry into clinical trials for Transcatheter Mitral Valve Replacement System		
		Commencement of clinical trial for Interventional Left Ventricular Assist System	Entry into clinical trials for Implantable Ventricular Assist System		

Project Stage/Time	2026	2027	2028	2029	2030
		Entry into clinical trials for MemoSorb® Biodegradable Patent Ductus Arteriosus Occluder Entry into clinical trials for Transcatheter Aortic Valve System (TAVR for regurgitation indication) Entry into clinical trials for Dense Mesh Left Atrial Appendage Occluder Entry into clinical trials for Biodegradable Aortic Embolisation Occluder Entry into clinical trials for Vascular Plug Entry into clinical trials for Atrial Shunt Device I			
Pre-clinical Validation		Entry into type inspection and animal test for Aortic Dissection Occluder			

Congenital Heart Disease Occluder Products

As of the date of this announcement, the Group has a total of 11 commercialized congenital heart disease occluder products. Among these, the second-generation MemoCarna® Oxide Coating Single-Rivet Occluder series products have become a major component of the congenital heart disease occluder product line since their approval for marketing in 2020. Following the marketing approval of the third-generation MemoSorb® Fully Biodegradable Occluder System in 2022, the third-generation MemoSorb® Biodegradable Atrial Septal Defect Occluder product also obtained a medical device registration certificate issued by the National Medical Products Administration in August 2024. Currently, both of the aforementioned products have been commercialized, providing more options for clinical interventional treatment of congenital heart disease and forming the Group's core product portfolio in the field of congenital heart occluders.

Building on over 20 years of technological accumulation and continuous product iteration and upgrades, the Group maintains a leading position in the field of congenital heart disease occluders. In the domestic market, the Group will continue to promote the increase in market penetration of its oxide coating and biodegradable occluder series; in overseas markets, the Group has accelerated its deployment, effectively offsetting the revenue impact from the centralized procurement of occluders in the domestic market through product iteration and upgrades and continuous expansion into international markets, thereby forming a business landscape of synergistic growth in both domestic and overseas markets. The Group will also, through an external expansion strategy, propel its various businesses into a new phase of rapid growth while consolidating its existing advantages.

In line with our technological philosophy of "Implantation without Residue", the Group will continue to promote the research and development and application of biodegradable material, and is committed to extending degradable-related technologies to the clinical practice of more medical device products.

Cardioembolic Stroke Prevention Products

The field of cardioembolic stroke prevention is currently one of the fastest-growing segments in the interventional structural heart disease treatment market. The Group places great importance on its market presence in this field. Through the synergistic advancement of its biodegradable technology platform and traditional metal occluder product lines, it has established a multi-product collaborative model ranging from screening and diagnosis to interventional surgical support and implantable product treatment. Its product pipeline covers the full range of indications for patent foramen ovale (PFO) and left atrial appendage occluder, continuously enhancing its market competitiveness.

Regarding products already on the market, the third-generation MemoSorb® Biodegradable PFO Occluder was approved for marketing in September 2023. This product is based on the Group's technological concept of "Implantation without Residue" and is currently the Group's flagship product in the field of cardioembolic stroke prevention. Since its launch, it has been progressively applied in clinical practice, offering a new treatment option for PFO occlusion procedures. Regarding products under development, the Bio-Lefort® Biodegradable Left Atrial Appendage Occluder has completed all patient enrollment for its multi-center randomized controlled clinical trial and is currently progressing with subsequent clinical follow-ups and registration data compilation, with an NMPA registration application expected to be completed in the second half of 2026. The MemoCarna® Oxide Coating PFO Occluder completed its registration application in 2025 and is currently in the review stage, with registration approval expected to be obtained in the fourth quarter of 2026. The Dense Mesh Left Atrial Appendage Occluder has completed project initiation and design finalization, and is planned to enter the type inspection and animal test stage in the second half of 2026, with clinical trials commencing in the second half of 2027.

In addition, the Group's independently developed ultrasound contrast injection device, primarily used for the bubble test in PFO screening, can effectively improve the accuracy and sensitivity of screening, forming a strong synergy with occluder products for pre-operative screening and intra-operative support. The device completed type inspection and animal test in 2025 and has now entered the large-scale clinical trial phase.

Regarding its overseas market deployment, the Group has accelerated the international patent layout and overseas registration process for its products in the field of cardioembolic stroke. As of the date of this announcement, the biodegradable and metallic PFO occluders (including accessories) have obtained a total of 26 overseas registration certificates. The Group will continue to advance the registration and commercialization of products in this field in overseas markets, effectively addressing the price pressure brought by domestic centralized procurement through the expansion of international markets.

The Group will continue to advance the research and development and application of biodegradable technology in the field of cardioembolic stroke prevention. Through product iteration and technological leadership, from PFO to left atrial appendage occluders, combined with synergistic development across multiple product lines and continuous expansion into overseas markets, the Group will further enrich its product portfolio in this field, providing clinical solutions covering the entire process from screening and intraoperative support to implant treatment.

Aortic and Peripheral Occluders

The Group, based on its biodegradable technology platform and nitinol braiding technology platform, extends its technological advantages and innovative applications from the cardiac field to the aortic and peripheral fields, continuously expanding its product pipeline.

In the aortic field, the Group has deployed two products. The Biodegradable Aortic Occluder is used for the treatment of distal entry tears in aortic dissection. Through minimally invasive interventional surgery, it precisely occludes the entry tear, preventing the dissection from expanding or rupturing, while preserving blood flow to important vessels, improving distal organ blood supply, reducing postoperative complications and lowering surgical risks. This represents an innovative and expanded application of biodegradable technology. The product has completed FIM (First-in-Man trial) enrollment and has entered the large-scale clinical trial phase, with clinical enrollment expected to be completed by the end of 2027. The Aortic Embolisation Occluder is designed for Type II endoleaks after endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms. It adopts a self-expanding structure with dense mesh weaving, which can maintain full expansion in tortuous and complex spaces, efficiently fill the aneurysm sac, promote thrombosis, effectively reduce the size of the aneurysm sac and lower the risk of rupture. The product is currently in the large-scale clinical trial phase, with clinical results meeting expectations. Patient enrollment will accelerate in the second half of the year, and all enrollment is expected to be completed by the end of 2026.

Currently, treatment for distal entry tears in aortic dissection primarily involves open-chest surgical replacement with an artificial blood vessel and interventional endovascular stent-graft isolation therapy. There are no approved biodegradable occluder products specifically for sealing aortic dissection entry tears on the market. Furthermore, there is a lack of commercialized, targeted, specialized treatment devices for Type II endoleaks following endovascular repair of abdominal aortic aneurysms. The Group's two aforementioned products are both world-leading innovative products.

In the peripheral field, the Group has two vascular plug products in its pipeline. The Vascular Plug is in the pre-clinical stage and is expected to enter clinical trials by the end of 2027; the Biodegradable Vascular Plug is currently undergoing type inspection and animal test and is expected to enter the clinical trial stage in the fourth quarter of 2026.

The Group will continue to rely on its two major technology platforms to promote the research and development and clinical translation of innovative products in the aortic and peripheral fields, providing more comprehensive treatment solutions for clinical applications.

Heart Valve Product Candidates

The Group's products in the heart valve field mainly cover aortic valve and mitral valve products.

The ScienCrown® Transcatheter Aortic Valve System officially entered the commercialization stage in early 2025. To date, the product has been implanted in over 200 clinical centers domestically. While continuously advancing the domestic commercialization process, the Group is also simultaneously advancing the overseas registration layout for the product.

The transcatheter aortic valve product under development, intended for patients with simple aortic regurgitation, has undergone design optimization based on the technical foundation of the ScienCrown® system, retaining its retrievability advantage and incorporating a clamping positioning design and angulation function. The product has currently completed animal experiments and type testing, and is expected to enter the clinical trial stage in 2027.

Regarding the mitral valve clip repair system, the transapical pathway product is undergoing clinical trials, with all patient enrollment expected to be completed in the second half of 2026, after which it will enter the post-operative follow-up phase.

The Group will continue to advance the clinical development and commercial application of products in the heart valve sector.

Mechanical Circulatory Support Products

The Group has expanded into the field of mechanical circulatory support (MCS) devices. The product line covers both short-term support and long-term support categories, which are designed to assist or replace the pumping function of the ventricles, specifically including the interventional left ventricular support system and the implantable left ventricular support system.

Among them, the indications for the interventional left ventricular support system suitable for short-term support include high-risk percutaneous coronary interventions (PCI), cardioembolic shock and critical care emergencies. The product is currently in the type inspection and animal test stage, and it plans to initiate clinical trials in the first half of 2027.

Based on the technological advantages and clinical resources accumulated in the passive cardiovascular medical device field, the Group is gradually expanding into the active medical device technology platform. As an important direction for the treatment of heart failure related to structural heart disease, MCS devices are a key layout area for the Group to broaden its product pipeline and form new growth points. The Group will continue to advance the research and development and clinical translation of products in this field, continuously launch innovative products, and perfect comprehensive solutions from diagnosis to treatment, and from passive to active.

Pathway Products

Pathway products mainly include related products that provide supporting facilities for surgeries involving occluders, heart valves and other major implantable devices, covering categories such as puncture systems, delivery systems, guiding systems and valve procedural accessories.

In the cardioembolic stroke prevention field, the Group has established a relatively complete supporting system for pathway products centered around LAA occluder implantation. Among them, the traditional atrial septal puncture needle and the RF-Lance® radiofrequency atrial septal puncture system have both been approved for marketing, providing diversified atrial septal puncture solutions for LAA occlusion surgeries; the dedicated delivery system used for biodegradable LAA occluder implantation has also obtained the registration certificate and been launched for sale in 2025.

In the fields of congenital heart disease and PFO occlusion, the multi-functional interventional guide wires were approved for marketing in the PRC in November 2025, primarily providing supporting facilities for the implantation of CHD ASD and PFO occluders, which can effectively improve surgical operation efficiency.

In terms of supporting accessories for heart valve surgeries, the balloon dilatation catheter for aortic valve received registration approval from the NMPA at the end of 2024, the super stiff guidewire was approved for marketing in September 2025, and the thrombus protection device has also completed commercialization. In addition, the vascular closure system is currently in the preparation stage of registration materials. The product adopts an innovative design structure, which can reduce vascular complications, and is expected to submit the NMPA registration application in September 2026. In the aortic and peripheral occlusion field, the deflectable aortic delivery system supporting aortic occluder surgeries is currently in the type inspection stage and is expected to submit the NMPA registration application in 2027.

The Group will continually optimize and expand its pathway product portfolio, ensuring clinicians have access to the most comprehensive and reliable supporting solutions for all types of implant surgeries.

Centralized Volume-based Procurement and Price Governance of Medical Consumables for Structural Cardiology Occluders

In November 2025, the Fujian Provincial Healthcare Security Bureau led the initiation of the inter-provincial Centralized Volume-based Procurement of Medical Consumables for Structural Cardiology Occluders. This centralized procurement covers 31 provinces/municipalities/autonomous regions across the country. The varieties covered by this centralized procurement include atrial septal defect occluders, ventricular septal defect occluders, patent ductus arteriosus occluders and left atrial appendage occluders (all including delivery systems), and biodegradable occluders and their delivery systems are not included in the scope of centralized procurement. The Group's first-generation and second-generation CHD occluder products (including the oxide coating series) and LAA occluder products are all included in the bid-winning catalog of the centralized procurement.

With respect to implementation progress, as of the date of this announcement, except for Shanghai (which will implement on August 25, 2026) and Chongqing (which will implement on September 1, 2026), the remaining 29 provinces and municipalities have entered the implementation phase for ASD occluders, VSD occluders, PDA occluders (including their delivery systems). For LAA occluders and their delivery systems, except for Shanghai and Chongqing, 29 provinces and municipalities have also entered the implementation phase, of which Liaoning Province, Guangxi Zhuang Autonomous Region, Hebei Province, Yunnan Province, Qinghai Province, Xinjiang Uygur Autonomous Region, Guizhou Province and Xizang Autonomous Region followed the project of the Sanming Procurement Alliance, while Anhui Province followed its own provincial centralized procurement project. The bid-winning results of this centralized procurement were announced in January 2026, and have been gradually implemented across all provinces in China since April 28, 2026.

Affected by this centralized procurement, distributors still adopted a wait-and-see attitude in the first quarter of 2026 and did not replenish their stock as expected, which had a certain impact on the performance of the related occluders. The price reduction in this centralized procurement is within the Group's acceptable range, and it is expected that the performance of metal occluders and related pathway products will tend to stabilize in the second half of the year.

In addition, the National Healthcare Security Administration launched the price governance initiatives for the first batch of high-value medical consumables in 2026, covering related products of the Group, such as aortic interventional valves and accessories, biodegradable occluders and delivery systems, and radiofrequency puncture needles. The terminal prices of the aforementioned products have been slightly adjusted downward, with all declines falling within the range expected by the Group's management. The new price adjustments are more aligned with the orientation of national medical insurance policies, which will help further accelerate the penetration and promotion of relevant products in the domestic market. Among them, the biodegradable occluders, whose price adjustment was in line with medical insurance policies and have not been included in the scope of centralized procurement, are expected to accelerate their clinical promotion and application in the second half of the year, helping the Company's revenue return to the growth track.

OUTLOOK

Looking forward, the Group will continue to be committed to providing safe, effective, innovative and comprehensive medical solutions in the pan-cardiovascular disease-related medical device fields.

The Group will continue to advance the exploration and development of new technologies, focusing on the core technologies and product development in the structural heart disease field, to further enrich the product portfolio and comprehensively cover the treatment options for various sub-fields of structural heart disease. In aspects such as design concepts, material science, structural design and production processes, the Group will continue to optimize to enhance the innovation, functionality and reliability of its products. The Group believes that biodegradable technology is one of the important technological directions for medical device products in the future, and its application in products such as occluders has gradually validated its clinical value, which is expected to drive structural changes in the domestic medical market and promote the overall transformation and upgrade of the medical device industry. Relying on this technology platform, the Group will seize market opportunities, deepen the layout of the existing market, and expand incremental market space.

In the field of congenital heart disease interventional therapy devices, the Group will leverage the market foundation and technological advantages accumulated over 20 years of in-depth development to continue to increase the speed of iteration and upgrade of innovative products. In terms of overseas market expansion, as of the date of this announcement, the Group's first-generation metal occluders and accessories have obtained a total of 167 registration certificates, the second-generation MemoCarna® oxide coating occluders and accessories have obtained a total of 18 registration certificates, and the third-generation MemoSorb® biodegradable CHD occluders and accessories have obtained a total of 18 registration certificates. The above products have achieved market access in multiple countries and regions. The continuous expansion of overseas markets will effectively offset the price pressure brought by domestic centralized procurement, becoming an important growth support for the Group's CHD occluder business. The Group will further expedite the international registration and commercialization of its innovative pipeline, securing an ever-larger share of the global market.

In the cardioembolic stroke prevention field, the Group will continue to promote the research and development and registration of new PFO occluder and LAA occluder products. The MemoCarna® oxide coating PFO occluder is expected to obtain the registration certificate in the fourth quarter of 2026, which will further enrich the metal PFO occluder product line; the dense mesh LAA occluder has completed project initiation and design finalization, and is planned to enter the type inspection and animal test stage in the second half of 2026, and initiate clinical trials in the second half of 2027; the Bio-Lefort® biodegradable LAA occluder is expected to submit the NMPA registration application in the second half of 2026, and be approved in 2027. In terms of the overseas market, as of the date of this announcement, the Group's biodegradable and metal PFO occluders (including accessories) have obtained a total of 26 registration certificates. The Group will continue to strengthen the commercialization promotion of marketed products. As the flagship product in this field, the third-generation MemoSorb® biodegradable PFO occluder has achieved good market performance. The Group will further strengthen academic exchanges with clinical surgeons, improve channel construction, and enhance the market penetration rate of the product. The Group believes that the application of biodegradable technology in this field has early-mover advantages. Combined with excellent product performance and continuously improving sales networks, as well as the synergistic layout of multiple product lines, it will effectively enhance the Group's market competitiveness in the cardioembolic stroke prevention field, fully seizing the development opportunities brought by domestic market growth and low penetration rate.

In the valve stenosis and reflux therapy field, the Group will rely on the existing valve product technology platform, uphold a steady strategy, and continuously optimize the multi-valve product portfolio while continuing to promote technological innovation, covering core indications such as aortic and mitral valves. The Group will accelerate the advancement of the clinical process of iterative new products based on the ScienCrown® system, and develop differentiated transcatheter aortic valve systems for patients with simple aortic regurgitation, forming a multi-level product matrix to address the clinical demands of different types of valve diseases. In terms of overseas markets, the Group will actively promote patent layouts and product innovation designs, accelerate the registration and commercialization process of valve products in overseas markets, further expand international market space, and enhance global competitiveness.

In the aortic and peripheral fields, the Group has extended its technological advantages from the cardiac field to the aortic and peripheral fields, which is an important new growth pipeline for the Group in the future. Currently, the biodegradable aortic occluder has completed FIM enrollment and entered the large-scale clinical trial stage, expecting to complete clinical enrollment by the end of 2027; the aortic embolization occluder is in the large-scale clinical trial stage, with clinical results meeting expectations, expecting to complete enrollment work by the end of 2026. Both of these products are world-leading innovative products, and there are currently no similar products approved for marketing, presenting broad market prospects. In the peripheral field, the vascular plug is expected to enter clinical trials by the end of 2027, and the biodegradable vascular plug has completed type inspection and animal tests, expecting to enter the clinical trial stage in the fourth quarter of 2026. The Group will continue to rely on the biodegradable technology platform and the nitinol wire weaving technology platform to accelerate the research and development and clinical translation of innovative products in the aortic and peripheral fields, actively layout overseas patents and registrations, provide more comprehensive treatment solutions for clinical practices, and form new business growth drivers.

In the mechanical circulatory support field, as an important "bridge" treatment method for patients with acute cardiac events and end-stage heart failure, MCS technology is being increasingly widely applied clinically. It is estimated that approximately 15.35 million patients in China and more than 64 million patients globally suffer from cardiac insufficiency problems, and about 50% of patients will die within five years after diagnosis. From 2025 to 2030, the global market size of MCS is expected to grow at a compound annual growth rate of more than 10%, with a market size expected to reach approximately USD5.59 billion in 2030. The Group will continue to strengthen its layout in the field of heart failure treatment related to structural heart disease, gradually expanding from passive technology platforms to active technology platforms. Through the research and development and commercialization of innovative products such as MCS, it will broaden the product pipeline and form new growth momentum.

The Group has established four professional marketing teams for congenital heart disease, electrophysiology, valves and international trade, continuously expanding sales channels, and accelerating the market penetration of products in various pipelines domestically through the implementation of centralized procurement. The Group will consolidate and deepen communication and cooperation with research institutions, hospitals, clinicians and industry experts, continuously obtain clinical feedback and market information, optimize product design and production processes, enhance sales service capabilities, and better serve doctors and patients with better products and a more complete service system. While products in various pipelines accelerate penetration in the domestic market, the Group is also simultaneously accelerating the strategic layout of its overseas business.

In terms of overseas business, the Group will actively expand overseas sales channels with global insight, explore the market potential of existing products, increase market penetration rates, and build up a good reputation for its products and brand image in the international market. The Group will continue to keep abreast of global market development trends, clinical demands and market competition landscape, reasonably plan overseas clinical trials and registration strategies, and advance the commercialization process of innovative products such as biodegradable occluders and valves in overseas markets in due course, so as to ensure the sustainable development of overseas business and promote the steady implementation of the internationalization strategy.

FINANCIAL REVIEW

Revenue

Our revenue is mainly derived from the sales of medical devices through distributors and direct sales. The following table sets forth a breakdown of our revenue by major products for the six months ended June 30, 2025 and 2026 (presented in absolute amounts and as percentages of our total revenue).

	Six months ended June 30,				
	2026		2025		Change
	RMB	***%***	*RMB*	*%*	*%*
CHD occluder products	**122,076,462.82**	**39.4**	160,628,028.37	48.7	-24.0
Cardioembolic stroke prevention products	**122,942,964.30**	**39.7**	81,656,574.20	24.8	50.6
Pathway products	**43,831,652.67**	**14.1**	47,192,209.59	14.3	-7.1
Heart valve products	**21,206,568.48**	**6.8**	40,125,415.38	12.2	-47.1
Other products	**78,986.32**	**0.0**	103,111.24	0.0	-23.4
Total	**310,136,634.59**	**100.0**	329,705,338.78	100.0	-5.9

Our revenue decreased by 5.9% from RMB329.7 million for the six months ended June 30, 2025 to RMB310.1 million for the six months ended June 30, 2026.

CHD occluder products

Revenue generated from sales of the Group's CHD occluder products decreased by 24.0% from RMB160.6 million for the six months ended June 30, 2025 to RMB122.1 million for the six months ended June 30, 2026, and the decrease in revenue was primarily due to the following reasons: in November 2025, the Fujian Provincial Healthcare Security Bureau led the initiation of the inter-provincial Centralized Volume-based Procurement of Medical Consumables for Structural Cardiology Occluders, and the Group's first-generation and second-generation CHD occluder products (including the oxide coating series) and their delivery systems were all included in the scope of the centralized procurement. Affected by the dual impact of distributors adopting a wait-and-see attitude and not replenishing their stock as expected before the implementation of the specific measures of the centralized procurement, and the product price reduction after the implementation of the centralized procurement, the revenue generated from sales of the Group's CHD occluder products ultimately decreased as compared to the corresponding period last year. However, the price reduction of this centralized procurement was within the Group's acceptable range and with the implementation of the selected results of the centralized procurement in April 2026, we expect the impact of the centralized procurement on our performance to gradually decrease in the second half of the year, and our overall performance will gradually stabilize. Meanwhile, the Group's products of biodegradable series have not been included in the scope of the centralized procurement, and we will continue to enrich the product pipeline of biodegradable technology, fully leverage the leading advantages of biodegradable technology, promote product iteration, build a differentiated competitive landscape for products, and drive the Group's performance to return to the growth track at an early date.

Cardioembolic stroke prevention products

Our cardioembolic stroke prevention products primarily include PFO and LAA occluders, and revenue generated from sales of these products increased by 50.6% from RMB81.7 million for the six months ended June 30, 2025 to RMB122.9 million for the six months ended June 30, 2026. The revenue from the product line was mainly derived from the sales of third-generation MemoSorb® biodegradable PFO occluders. Due to innovative incorporation of biodegradable technology, the products have gained widespread attention in the market since their launch in the second half of 2023, and won high recognition from both clinical applications and patients. Against the backdrop of the market adopting a wait-and-see attitude towards traditional metal occluders due to the impact of the centralized procurement, the Group's third-generation MemoSorb® biodegradable PFO occluder products, which were not included in the scope of the centralized procurement, showed a good trend of simultaneous increase in volume and price in the current period, with sales volume increasing by over 35% year-on-year, which to a certain extent compensated for the adverse impact on CHD products brought by the centralized procurement. With the continuous acceleration of the commercialization process in the second half of the year, we believe the Group's products of biodegradable series will benefit more patients and also bring even more outstanding commercialization results to the Company.

Pathway products

Our pathway products primarily include interventional delivery systems and snares mainly related to CHD occluder products. Revenue generated from sales of the Group's pathway products decreased by 7.1% from RMB47.2 million for the six months ended June 30, 2025 to RMB43.8 million for the six months ended June 30, 2026. Revenue generated from sales of interventional delivery systems was the largest source of our revenue generated from sales of pathway products, and the decrease was primarily attributable to the impact of the centralized volume-based procurement, resulting in a decrease in the sales volume of our various occluder products included in the scope of the centralized procurement, and the corresponding decrease in the sales volume of our related procedural accessories.

Heart valve products

The Group's ScienCrown® TAVR system received registration approval from the NMPA at the end of 2024 and has officially achieved commercialization in early 2025. With the unique structural design, superior product quality and comprehensive sales channels, both market coverage and implantation volume of the product have achieved rapid growth after its launch.

During the Reporting Period, the sales revenue of our heart valve products decreased by RMB18.9 million as compared to the corresponding period last year, primarily due to the fact that the National Healthcare Security Administration launched the price governance initiatives for the first batch of high-value medical consumables in 2026, affected by which, the terminal prices of the heart valve products have been slightly adjusted downward. In addition, affected by the multi-product bundled charging model, the revenue from supporting consumables and accessories has also declined, which has simultaneously impacted distributors' short-term confidence in restocking. However, all the aforementioned price declines are well within the range expected by the Group's management. With the implementation of price adjustments, the ScienCrown® TAVR product has achieved a significant year-on-year increase in both the number of covered hospitals and implantation volume, with its market penetration rate continuing to rise.

While continuing to promote the domestic commercialization process, the Group was also simultaneously advancing the overseas registration layout of the product, with a view to obtaining broader market space. Meanwhile, the progress of pipeline products including the transcatheter aortic valve system for patients with aortic regurgitation and the mitral valve clip repair system was advancing as scheduled, aiming to gradually enrich the heart valve product pipeline and promote the products of the heart valve series to become another stable revenue growth curve for the Group sooner.

Operating cost

The following table sets forth our cost of sales by nature in absolute amounts and as percentages of our total cost of sales for the six months ended June 30, 2025 and 2026.

	Six months ended June 30,				
	2026		2025		Change
	RMB	***%***	*RMB*	*%*	*%*
Raw materials and consumables	**27,913,955.77**	**50.1**	25,144,621.05	55.4	11.0
Labor costs	**7,674,114.86**	**13.8**	8,003,887.50	17.6	-4.1
Amortization of intangible assets	**17,336,296.19**	**31.1**	9,498,822.85	20.9	82.5
Depreciation of property, plant and equipment	**992,652.20**	**1.9**	851,437.70	1.9	16.6
Transportation costs	**404,481.95**	**0.7**	550,245.83	1.3	-26.5
Utilities and office expenses	**830,559.90**	**1.5**	516,334.57	1.1	60.9
Others	**527,297.45**	**0.9**	792,791.85	1.7	-33.5
Total	**55,679,358.32**	**100.0**	45,358,141.35	100.0	22.8

Our operating cost primarily consisted of (i) raw materials and consumables; (ii) labor costs; (iii) amortization of intangible assets; (iv) depreciation of property, plant and equipment; (v) transportation costs; (vi) utilities and office expenses; and (vii) others. Our operating cost increased by 22.8% from RMB45.4 million for the six months ended June 30, 2025 to RMB55.7 million for the six months ended June 30, 2026.

(i) Our raw materials and consumables costs used during the manufacturing process increased by RMB2.8 million from RMB25.1 million for the six months ended June 30, 2025 to RMB27.9 million for the six months ended June 30, 2026, which was primarily attributable to a substantial increase in the sales volume of the Group's biodegradable occluders and their delivery systems not included in the centralized procurement scope in the current period as compared to the corresponding period last year, resulting in an increase in corresponding material costs, which was partially offset by a decrease in the material costs of traditional metal occluders and their delivery systems included in the centralized procurement.

(ii) Our amortization of intangible assets increased by RMB7.8 million from RMB9.5 million for the six months ended June 30, 2025 to RMB17.3 million for the six months ended June 30, 2026, which was primarily attributable to the successive approvals from the NMPA and commercialization of a number of our self-developed and new products, with the corresponding capitalized R&D expenditure being subsequently transferred to intangible assets and the commencement of amortization, which resulted in an increase in our amortization of intangible assets as compared to the corresponding period last year.

Gross profit

Our gross profit decreased by 10.5% from RMB284.3 million for the six months ended June 30, 2025 to RMB254.5 million for the six months ended June 30, 2026.

Taxes and surcharges

Our taxes and surcharges primarily included (i) urban maintenance and construction tax; (ii) education surcharge; (iii) local education surcharge; (iv) property tax; (v) stamp duty; and (vi) land use tax. Our taxes and surcharges decreased by 21.0% from RMB4.3 million for the six months ended June 30, 2025 to RMB3.4 million for the six months ended June 30, 2026, which was primarily attributable to the change of the overall revenue and cost of the Company, collectively resulting in the decreases in urban maintenance and construction tax, education surcharge, local education surcharge and stamp duty.

Selling expenses

Our selling expenses primarily included (i) labor costs; (ii) travel and transportation fees; (iii) market fees; (iv) exhibition fees; (v) business entertainment fees; and (vi) business promotion fees. Our selling expenses increased by 29.2% from RMB43.3 million for the six months ended June 30, 2025 to RMB55.9 million for the six months ended June 30, 2026, which was primarily attributable to (i) an increase of RMB5.6 million in labor costs as a result of the Group's business development needs to expand the marketing team and increase marketing personnel and (ii) a total increase of approximately RMB7.5 million in various fees such as market fees, travel and transportation fees and exhibition fees, due to the successful commercialization of several new products of the Group, resulting in the significant increase of marketing activities of the Group for the current period as compared to the corresponding period last year.

Administrative expenses

Our administrative expenses primarily consisted of (i) labor costs; (ii) consulting service fees; (iii) share-based payment; (iv) depreciation and amortization expenses; (v) auditor's remuneration; (vi) travel and transportation expenses; and (vii) office expenses, etc. Our administrative expenses decreased by 37.8% from RMB14.6 million for the six months ended June 30, 2025 to RMB9.1 million for the six months ended June 30, 2026, which was primarily attributable to the expiration of the Group's Employee Share Ownership Plan of 2021 in October 2025, resulting in a decrease in related share-based payment expenses of RMB3.9 million as compared to the corresponding period last year.

Research and development expenses

Our research and development expenses primarily consisted of (i) labor costs; (ii) materials, power and manufacturing inspection fees; (iii) depreciation and amortization expenses; (iv) design and clinical trial fees; (v) share-based payment; (vi) outsourced research and development expenses; and (vii) other expenses. Our research and development expenses decreased by 22.9% from RMB25.4 million for the six months ended June 30, 2025 to RMB19.5 million for the six months ended June 30, 2026, which was primarily due to (i) a decrease in labor costs of RMB1.7 million; (ii) a decrease in materials, power and manufacturing inspection fees of RMB1.0 million due to the different stages of the research and development projects; and (iii) a decrease in related share-based payment expenses of RMB2.7 million as compared to the corresponding period last year as a result of the expiration of the Group's Employee Share Ownership Plan of 2021 in October 2025.

Financial expenses

Our financial expenses primarily consisted of (i) interest expenses; (ii) interest income; (iii) exchange gains or losses; and (iv) handling charges. Our financial expenses increased by 144.7% from RMB-9.9 million for the six months ended June 30, 2025 to RMB4.4 million for the six months ended June 30, 2026, primarily due to (i) a decrease in interest income of RMB5.2 million during the Reporting Period as compared to the corresponding period last year due to the continuous decrease in interest rates on various types of domestic deposits; and (ii) an increase in exchange losses of RMB9.1 million during the Reporting Period as compared to the corresponding period last year as affected by the change in foreign exchange rates.

Loss on impairment of credit

Our loss on impairment of credit primarily represented provision for impairment of accounts receivable and other receivables during the Reporting Period. Our loss on impairment of credit increased by 92.1% from RMB2.4 million for the six months ended June 30, 2025 to RMB4.7 million for the six months ended June 30, 2026, primarily due to the increase in the balance of accounts receivable and the change in ageing structure of the Group, causing a change in the expected credit loss rate of accounts receivable, and a period-on-period increase in the provision for impairment of credit calculated accordingly.

Income tax expenses

Our income tax expenses decreased by 17.4% from RMB28.7 million for the six months ended June 30, 2025 to RMB23.7 million for the six months ended June 30, 2026, which was primarily attributable to: (i) the change in the Group's performance, resulting in a decrease in taxable income for the current period as compared to the corresponding period last year; and (ii) the enhanced tax-saving effect from the additional deduction of amortization expenses related to self-developed intangible assets as a result of the advancement of the commercialization process of the Company's self-developed products, effectively reducing the Group's tax burden.

Net profit

As a result of the foregoing, our net profit for the Reporting Period decreased by 19.5% from RMB182.0 million for the six months ended June 30, 2025 to RMB146.5 million for the six months ended June 30, 2026.

LIQUIDITY, FINANCIAL RESOURCES AND CAPITAL STRUCTURE

The primary uses of cash are to fund the daily operations of the business of the Group. For the six months ended June 30, 2026, the Group principally used cash generated from its operating and financing activities and net proceeds from the Global Offering to meet its demand of capital expenditures and working capital. Going forward, the Company believes that its liquidity requirements will be satisfied with a combination of cash flows generated from our operating activities and other funds raised from the capital markets from time to time. As of June 30, 2026, the Group had not used any financial instruments for hedging purposes.

Cash flows

As of June 30, 2026, our cash and cash equivalents were denominated in RMB, HK dollar, USD and Euro dollars. Our total cash and cash equivalents increased by 7.2% from RMB1,151.3 million as of December 31, 2025 to RMB1,233.8 million as of June 30, 2026, which was primarily attributable to the net cash generated from operating activities of the Group of RMB146.8 million during the Reporting Period, partially offset by the net cash used in investing activities of RMB49.1 million, which primarily represented expenditure for research and development expenses of capitalization and purchase of equipment during the Reporting Period; the net cash used in financing activities of RMB6.9 million, which primarily represented expenditure for repurchase of Shares during the Reporting Period, and exchange loss on cash and cash equivalents of RMB8.3 million, a combination of which caused an increase in the balance of cash and cash equivalents at the end of the Reporting Period.

Borrowings

As of June 30, 2025 and 2026, we had no outstanding balance of borrowings or unutilized banking facilities.

Net current assets

Our net current assets decreased by 3.0% from RMB1,367.6 million as of December 31, 2025 to RMB1,327.1 million as of June 30, 2026. Our net current assets position as of the above dates was mainly attributable to the change of our cash at bank and on hand, financial assets held for trading, accounts receivable, inventories, prepayments, other receivables and certificates of deposit due within one year, partially offset by the change of our accounts payable, contract liabilities, other payables, employee benefits payable, taxes payable and lease liabilities due within one year.

Material Acquisitions and Disposals and Significant Investments

We did not have any material acquisitions and disposals and significant investments during the six months ended June 30, 2026.

Pledge of Assets

As of June 30, 2026, we did not pledge any of our assets.

Future Plans for Material Investments or Capital Assets

Save as disclosed in the sections headed "Events after the Reporting Period" and "Use of Net Proceeds from Listing" in this announcement and the section headed "Future Plans and Use of Proceeds" in the Prospectus, we did not have detailed future plans for material investments or capital assets as of the end of the Reporting Period.

Capital Expenditure

Our total capital expenditure decreased by 60.9% from approximately RMB40.4 million for the six months ended June 30, 2025 to approximately RMB15.8 million for the six months ended June 30, 2026. Our capital expenditure primarily included our purchase of equipment, purchase of intangible assets and payment for research and development expenses of capitalization. We funded these expenditures with cash generated from our operating and financing activities.

Capital Commitments

Our capital commitments decreased from approximately RMB2.5 million as of December 31, 2025 to approximately RMB0.4 million as of June 30, 2026, primarily in connection with purchase of equipment.

Contingent Liabilities

As of June 30, 2026, we did not have any material contingent liabilities.

Foreign Exchange Risk Management

Our functional currency is RMB. Foreign exchange risk arises when future commercial transactions or recognized assets and liabilities are denominated in a currency that is not our functional currency. We expose ourselves to foreign exchange risk because certain of our accounts payable, accounts receivable and cash at bank and on hand are denominated in foreign currencies. We will mitigate such a risk by constantly reviewing the economic situation and foreign exchange risk, and applying hedging measures when necessary.

Employee and Remuneration Policy

As of June 30, 2026, we had 371 full-time employees (December 31, 2025: 370), all of whom were based in China. The total staff costs for the six months ended June 30, 2026 (including staff remuneration, bonuses, welfare cost and social insurance fees etc.) amounted to approximately RMB51.0 million (including those capitalized staff costs of approximately RMB6.3 million).

We primarily recruit our employees through recruitment agencies, internal referrals and online recruiting channels, including our corporate website, job search websites and social networking platforms. We have adopted training protocols, pursuant to which we provide on-board and regular continuing trainings for our employees. As part of our human resources strategy, we offer employees competitive salaries, performance-based cash bonuses and other incentives.

Indebtedness

The following table sets forth the breakdown of our lease liabilities as of the dates indicated:–

	June 30, 2026	December 31, 2025
	RMB	*RMB*
	(Unaudited)	(Audited)
Lease liabilities	**586,253.28**	773,004.80

Key Financial Ratios

The following table sets forth our key financial ratios for the period/year indicated:–

	June 30, 2026	December 31, 2025
Liquidity ratio		
Current ratio	**6.5 times**	23.5 times
Gearing ratio	**10.7%**	3.0%

(1) The calculation of current ratio is based on current assets divided by current liabilities as of the end of the period/year.

(2) The gearing ratio is calculated based on the Group's total liabilities divided by total assets as of the end of the period/year.

Current ratio

Our current ratio was 6.5 times and 23.5 times as of June 30, 2026 and December 31, 2025, respectively. The decrease in current ratio was primarily due to the change in current assets and current liabilities as discussed in the section headed "Net current assets".

CONSOLIDATED BALANCE SHEET

(All amounts in RMB Yuan unless otherwise stated)

Assets	*Note*	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Current assets:			
Cash at bank and on hand		**1,237,255,472.66**	1,156,246,607.75
Settlement reserve			
Lending funds			
Financial assets held-for-trading		**50,000,000.00**	
Derivative financial assets			
Notes receivable			
Accounts receivable	*I*	**134,137,845.72**	85,051,296.90
Receivable financing			
Prepayments		**34,378,861.29**	36,923,406.74
Insurance contract assets*			
Reinsurance contract assets*			
Other receivables		**9,877,188.85**	9,375,110.56
Financial assets purchased under agreements to resell			
Inventories		**96,118,308.85**	111,151,006.27
Including: Data resources			
Contract assets			
Assets held for sale			
Non-current assets due within one year			21,730,068.51
Other current assets		**4,928,004.81**	7,833,268.01
Total current assets		**1,566,695,682.18**	1,428,310,764.74

Assets	*Note*	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Non-current assets:			
Loans and advances granted			
Debt investments			
Other debt investments			
Long-term receivables			
Long-term equity investments			
Investments in other equity instruments		**6,000,000.00**	
Other non-current financial assets			
Investment properties		**7,120,853.43**	7,231,179.27
Fixed assets	*II*	**107,958,152.48**	110,659,386.67
Construction in progress		**6,419,169.49**	6,984,576.85
Productive biological assets			
Oil and gas assets			
Right-of-use assets		**1,397,371.87**	2,381,155.48
Intangible assets		**214,851,527.92**	228,936,105.14
Including: Data resources			
Development expenses		**199,147,795.75**	181,683,937.31
Including: Data resources			
Goodwill		**48,281,830.04**	48,281,830.04
Long-term deferred expenses			
Deferred income tax assets		**12,802,833.41**	12,191,812.94
Other non-current assets		**73,658,412.43**	72,265,115.03
Total non-current assets		**677,637,946.82**	670,615,098.73
Total assets		**2,244,333,629.00**	2,098,925,863.47

Liabilities and owners' equity	*Note*	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Current liabilities:			
Short-term borrowings			
Loans from central bank			
Placements from banks and other financial institutions			
Financial liabilities held-for-trading			
Derivative financial liabilities			
Notes payable			
Accounts payable	*III*	**19,017,253.33**	17,775,678.64
Advances from customers			
Contract liabilities	*IV*	**13,950,452.16**	17,750,347.38
Securities sold under agreements to repurchase			
Deposits from customers and interbanks			
Receiving from vicariously traded securities			
Receiving from vicariously sold securities			
Employee benefits payable		**4,218,901.98**	5,116,369.97
Taxes payable		**23,549,897.39**	12,204,512.82
Other payables	*V*	**177,550,539.86**	6,400,990.27
Fee and commission payable			
Liabilities held for sale			
Non-current liabilities due within one year		**811,155.52**	942,187.98
Other current liabilities		**460,942.06**	484,883.90
Total current liabilities		**239,559,142.30**	60,674,970.96
Non-current liabilities:			
Insurance contract liabilities*			
Reinsurance contract liabilities*			
Long-term borrowings			
Bonds payable			
Including: Preference shares			
Perpetual bonds			
Lease liabilities		**586,253.28**	773,004.80
Long-term payable			
Long-term employee benefits payable			
Estimated liabilities			
Deferred income		**526,887.00**	526,887.00
Deferred income tax liabilities			
Other non-current liabilities			
Total non-current liabilities		**1,113,140.28**	1,299,891.80
Total liabilities		**240,672,282.58**	61,974,862.76

Liabilities and owners' equity	*Note*	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Owners' equity:			
Share capital		**346,749,997.00**	346,749,997.00
Other equity instruments			
Including: Preference shares			
Perpetual bonds			
Capital reserve		**1,346,692,045.84**	1,346,692,045.84
Less: Treasury shares		**6,455,979.77**	
Other comprehensive income			
Special reserve			
Surplus reserve		**43,595,510.70**	43,595,510.70
Provision for general risks			
Retained earnings		**273,079,772.65**	299,913,447.17
Total equity attributable to shareholders of the Company		**2,003,661,346.42**	2,036,951,000.71
Non-controlling interests			
Total owners' equity		**2,003,661,346.42**	2,036,951,000.71
Total liabilities and owners' equity		**2,244,333,629.00**	2,098,925,863.47

CONSOLIDATED INCOME STATEMENT

(All amounts in RMB Yuan unless otherwise stated)

Item		Note	Six months ended June 30, 2026 (Unaudited)	2025 (Unaudited)
I.	Total operating income		**310,136,634.59**	329,705,338.78
	Including: Operating income	*VI*	**310,136,634.59**	329,705,338.78
	Interest income			
	Insurance revenue			
	Income for handling charges and commissions			
II.	Total operating cost		**148,015,103.78**	123,008,408.82
	Including: Operating cost	*VI*	**55,679,358.32**	45,358,141.35
	Interest expense			
	Handling charges and commissions			
	Cost of insurance business			
	Taxes and surcharges		**3,406,184.86**	4,311,640.12
	Selling expenses		**55,881,323.35**	43,250,901.44
	Administrative expenses		**9,089,274.79**	14,605,208.57
	Research and development expenses		**19,549,476.00**	25,354,837.54
	Financial expenses		**4,409,486.46**	-9,872,320.20
	Including: Interest expenses		**26,666.49**	74,169.07
	Interest income		**4,280,608.21**	9,500,904.56
	Add: Other income		**10,220,193.10**	3,895,091.04
	Investment income (loss expressed with "-")		**2,590,952.86**	2,606,905.31
	Including: Income from investment in associates and joint ventures			
	Gains from derecognition of financial assets measured at amortised cost			
	Exchange gain (loss expressed with "-")			
	Net exposure hedging benefits (loss expressed with "-")			
	Gains from change in fair value (loss expressed with "-")			
	Loss on impairment of credit (loss expressed with "-")		**-4,660,011.39**	-2,425,491.73
	Loss on impairment of assets (loss expressed with "-")			
	Gains from disposal of asset (loss expressed with "-")		**16,645.09**	

Item		Note	Six months ended June 30, 2026 (Unaudited)	2025 (Unaudited)
III.	Operating profit (loss expressed with "-")		**170,289,310.47**	210,773,434.58
	Add: Non-operating income			
	Less: Non-operating expenses		**1,306.96**	5,609.34
IV.	Total profit before tax (total loss expressed with "-")		**170,288,003.51**	210,767,825.24
	Less: Income tax expense	*VII*	**23,746,679.53**	28,743,533.86
V.	Net profit (net loss expressed with "-")		**146,541,323.98**	182,024,291.38
	(I) Classified by continuity of operations			
	1. Net profit from continuing operations (net loss expressed with "-")		**146,541,323.98**	182,024,291.38
	2. Net profit from discontinued operations (net loss expressed with "-")			
	(II) Classified by ownership			
	1. Net profit attributable to shareholders of the parent company (net loss expressed with "-")		**146,541,323.98**	182,024,291.38
	2. Net profit attributable to non-controlling interests (net loss expressed with "-")			
VI.	Net other comprehensive income after tax			
	Net other comprehensive income after tax attributable to shareholders of the Company			
	(I) Other comprehensive income that may not be subsequently reclassified to profit and loss			
	1. Change in remeasurement of defined benefit plans			
	2. Share of other comprehensive income accounted for using equity method that will not be reclassified to profit or loss			
	3. Change in fair value of investments in other equity instruments			
	4. Changes in fair value of credit risks of the Company			
	5. Financial changes in insurance contracts issued that will not be reclassified to profit or loss			
	6. Others			

Item	*Note*	**Six months ended June 30, 2026 (Unaudited)**	2025 (Unaudited)
(II) Other comprehensive income that will be subsequently reclassified to profit or loss			
1. Share of other comprehensive income accounted for using equity method that will be reclassified to profit or loss			
2. Change in fair value of other debt investments			
3. Amount of financial assets reclassified into other comprehensive income			
4. Provision for credit impairment of other debt investments			
5. Cash flow hedging reserve			
6. Exchange differences arising from translation of foreign currency financial statements			
7. Financial changes in insurance contracts issued that will be reclassified to profit or loss			
8. Financial changes in reinsurance contracts held that will be reclassified to profit or loss			
9. Others			
Net other comprehensive income attributable to non-controlling interests after tax			
VII. Total comprehensive income		**146,541,323.98**	182,024,291.38
Total comprehensive income attributable to shareholders of the Company		**146,541,323.98**	182,024,291.38
Total comprehensive income attributable to non-controlling interests			
VIII. Earnings per share:			
(I) Basic earnings per share (RMB/share)		**0.4226**	0.5249
(II) Diluted earnings per share (RMB/share)		**0.4226**	0.5249

FINANCIAL NOTES

I. ACCOUNTS RECEIVABLE

1. Accounts receivable based on their entry dates shown by ageing

Ageing	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Within 1 year (inclusive)	**137,074,748.75**	90,002,916.56
1-2 years	**13,012,706.24**	7,964,502.38
2-3 years	**1,628,162.96**	
3-4 years		311,693.80
4-5 years	**311,693.80**	63,431.86
Over 5 years	**4,016,640.51**	3,953,208.65
Sub-total	**156,043,952.26**	102,295,753.25
Less: Provision for bad debts	**21,906,106.54**	17,244,456.35
Total	**134,137,845.72**	85,051,296.90

Note: The Group generally does not offer any official contractual credit terms to customers and will closely monitor the settlement pattern of respective customers. For certain individual customers with long-term relationship with the Group and have good credit history in the past, the Group may allow them to settle the related receivable balances within a discretionary period ranging from 30 days to 360 days.

2. Accounts receivable by method of bad debt provision

	As at June 30, 2026 (Unaudited)					As at December 31, 2025 (Audited)				
	Book balance		**Provision for bad debts**			Book balance		Provision for bad debts		
Type	**Amount**	**Percentage (%)**	**Amount**	**Percentage (%)**	**Carrying Value**	Amount	Percentage (%)	Amount	Percentage (%)	Carrying Value
Provision for bad debts made on an individual basis										
Provision for bad debts made on a grouping basis by credit risk characteristics	**156,043,952.26**	**100.00**	**21,906,106.54**	**14.04**	**134,137,845.72**	102,295,753.25	100.00	17,244,456.35	16.86	85,051,296.90
Including:										
Expected credit loss on a grouping basis	**144,117,460.12**	**92.36**	**21,906,106.54**	**15.20**	**122,211,353.58**	97,176,828.77	95.00	17,244,456.35	17.75	79,932,372.42
Related party on a grouping basis	**11,926,492.14**	**7.64**			**11,926,492.14**	5,118,924.48	5.00			5,118,924.48
Total	**156,043,952.26**		**21,906,106.54**		**134,137,845.72**	102,295,753.25		17,244,456.35		85,051,296.90

II. FIXED ASSETS

1. Fixed assets and disposal of fixed assets

Item	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Fixed assets	**107,958,152.48**	110,659,386.67
Total	**107,958,152.48**	110,659,386.67

2. Breakdown of fixed assets

Item		Buildings	Machinery and equipment	Transportation vehicle	Electronic devices and others	Total
1.	Original carrying amount					
	(1) As at December 31, 2025 (Audited)	104,450,615.43	56,706,751.08	2,333,970.77	5,703,229.49	169,194,566.77
	(2) Increase during this period	595,165.90	469,241.11		259,955.45	1,324,362.46
	– Purchase		469,241.11		259,955.45	729,196.56
	– Transferred from construction in progress	595,165.90				595,165.90
	(3) Decrease during this period		241,424.46	410,460.96	84,626.25	736,511.67
	– Disposal or retirement		241,424.46	410,460.96	84,626.25	736,511.67
	(4) As at June 30, 2026 (Unaudited)	105,045,781.33	56,934,567.73	1,923,509.81	5,878,558.69	169,782,417.56
2.	Accumulated depreciation					
	(1) As at December 31, 2025 (Audited)	27,662,401.75	24,864,025.32	2,021,524.35	3,987,228.68	58,535,180.10
	(2) Increase during this period	1,220,342.17	2,296,938.85	72,037.95	276,762.02	3,866,080.99
	– Provision made	1,220,342.17	2,296,938.85	72,037.95	276,762.02	3,866,080.99
	(3) Decrease during this period		134,796.18	389,937.91	52,261.92	576,996.01
	– Disposal or retirement		134,796.18	389,937.91	52,261.92	576,996.01
	(4) As at June 30, 2026 (Unaudited)	28,882,743.92	27,026,167.99	1,703,624.39	4,211,728.78	61,824,265.08
3.	Provision for impairment					
	(1) As at December 31, 2025 (Audited)					
	(2) Increase during this period					
	(3) Decrease during this period					
	(4) As at June 30, 2026 (Unaudited)					
4.	Carrying value					
	(1) Net book value at June 30, 2026 (Unaudited)	76,163,037.41	29,908,399.74	219,885.42	1,666,829.91	107,958,152.48
	(2) Net book value at December 31, 2025 (Audited)	76,788,213.68	31,842,725.76	312,446.42	1,716,000.81	110,659,386.67

III. ACCOUNTS PAYABLE

Accounts payable based on their entry dates shown by ageing

Item	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Within one year	**16,327,259.17**	15,417,454.75
1-2 years	**2,285,270.65**	1,961,841.46
2-3 years	**248,306.91**	242,864.99
Over 3 years	**156,416.60**	153,517.44
Total	**19,017,253.33**	17,775,678.64

Note: The credit period granted by suppliers to the Group ranged from 30 days to 120 days.

IV. CONTRACT LIABILITIES

Item	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Within one year	**13,950,452.16**	15,327,075.72
1-2 years		957,471.86
2-3 years		1,465,799.80
Over 3 years		
Total	**13,950,452.16**	17,750,347.38

V. OTHER PAYABLES

Item	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Dividends payable	**173,374,998.50**	
Other payables	**4,175,541.36**	6,400,990.27
Total	**177,550,539.86**	6,400,990.27

1. Dividends payable

Item	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Dividends for ordinary shares	**173,374,998.50**	
Total	**173,374,998.50**	

2. Other payables

Other payables by nature

Item	**As at June 30, 2026 (Unaudited)**	As at December 31, 2025 (Audited)
Current payments	**3,842,380.05**	4,806,139.03
Guarantee deposit	**114,838.07**	482,651.48
Others	**218,323.24**	1,112,199.76
Total	**4,175,541.36**	6,400,990.27

VI. OPERATING INCOME AND OPERATING COST

	Six months ended June 30,			
	2026 (Unaudited)		2025 (Unaudited)	
Item	**Revenue**	**Cost**	Revenue	Cost
Principal business	**310,057,648.27**	**55,569,032.48**	329,626,352.46	45,247,815.51
Other businesses	**78,986.32**	**110,325.84**	78,986.32	110,325.84
Total	**310,136,634.59**	**55,679,358.32**	329,705,338.78	45,358,141.35

VII. INCOME TAX EXPENSE

Item	**Six months ended June 30, 2026 (Unaudited)**	2025 (Unaudited)
Current income tax expenses	**24,357,700.00**	27,899,493.74
Deferred tax expenses	**-611,020.47**	844,040.12
Total	**23,746,679.53**	28,743,533.86

OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

The Company has from time to time since the date of its annual general meeting held on May 22, 2026 (the "**2025 AGM**"), repurchased the Shares on the open market, subject to market conditions and pursuant to the repurchase mandate obtained at the 2025 AGM. The timing, price and amount of repurchases will be determined based upon market conditions and other factors. For further details, please refer to the relevant announcement of the Company dated April 1, 2026.

During the Reporting Period, the Company has repurchased on the Stock Exchange a total of 740,000 Shares of the Company (the "**Shares Repurchased**") at a total consideration of approximately HK$7.4 million. Details of the Shares Repurchased are summarized as follows:

Month of repurchase	**Total number of shares repurchased**	**Repurchase price per share**		**Aggregate consideration**
		Highest	**Lowest**	
		HK$	*HK$*	*HK$*
June 2026	740,000	10.44	9.23	7,415,492

As at the date of this announcement, the Shares Repurchased are for cancellation but not yet canelled.

Save as disclosed above, neither the Company nor its subsidiaries had purchased, sold or redeemed any of the Company's listed securities (including sale of treasury shares, if any) during the six months ended June 30, 2026.

EVENTS AFTER THE REPORTING PERIOD

On August 21, 2026, the Company entered into the equity transfer agreement with Lepu Medical, pursuant to which the Company agreed to acquire 54.2384% of equity interest in Shanghai Minwei Biotechnology Co., Ltd.# (上海民為生物技術有限公司) (the "**Target Company**") held by Lepu Medical at a cash consideration of RMB1,088,387,980. The acquisition constituted a major transaction under Chapter 14 and a connected transaction under Chapter 14A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. For details, please refer to the announcement in relation to the major and connected transaction published by the Company on the same date.

As the agreement was entered into after the end of the Reporting Period, as of June 30, 2026, the Target Company was not consolidated into the financial statements of the Group. Upon completion of the transaction, its results and financial position will be reflected in the future financial statements.

Save as disclosed in this announcement, there are no any other material subsequent events required to be disclosed by the Group after June 30, 2026 and up to the date of this announcement.

USE OF NET PROCEEDS FROM LISTING

The Shares were listed on the Stock Exchange on the Listing Date. The net proceeds received from the Global Offering (after deducting the estimated underwriting commissions and other fees and expenses payable by the Company in connection with the Global Offering) were approximately HK$567.3 million.

The following table sets forth the planned use and actual use of the net proceeds from the Global Offering as of June 30, 2026:

Use of Proceeds	Net proceeds from the Global Offering *(HK$ million)*	Unutilized amount as of January 1, 2026 *(HK$ million)*	Utilized amount from January 1, 2026 to June 30, 2026 *(HK$ million)*	Unutilized amount as of June 30, 2026 *(HK$ million)*	Expected timeline for fully utilizing the unutilized amount[(1)]
To fund our research and development activities	287.6	90.4	17.7	72.7	Before December 31, 2027
For our sales and marketing activities	137.9	73.6	21.6	52.0	Before December 31, 2027
To expand our production capacity and strengthen our manufacturing capabilities	28.4	11.3	2.0	9.3	Before December 31, 2027
To fund potential strategic investments and acquisitions	56.7	24.9	–	24.9	Before December 31, 2027
For our working capital and general corporate purposes	56.7	30.4	–	30.4	Before December 31, 2027
Total	567.3	230.6	41.3	189.3	

Note:

(1) The expected timeline for fully utilizing the unutilized amount disclosed above is based on the best estimates made by the Board pursuant to the latest information up to the date of this announcement.

As disclosed on pages 485 to 492 of the Prospectus, based on the current business plan, the Company intended to implement the use of proceeds from the Global Offering in the five financial years from 2023 to 2027. The Board currently expects full utilization of the net proceeds raised from the Global Offering by December 31, 2027, subject to changes in light of the Company's evolving business needs and changing market conditions.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company's corporate governance practices are based on the principles and code provisions as set out in the CG Code contained in Appendix C1 to the Listing Rules and the Company has adopted the CG Code as its own code of corporate governance.

Throughout the Reporting Period, the Company has complied with the code provisions as set out in the CG Code, except for the deviation from the below code provision.

Pursuant to code provision C.2.1 in the CG Code as set out in Appendix C1 to the Listing Rules, the roles of chairman and chief executive officer should be separate and should not be performed by the same individual. Ms. Chen Juan (陳娟) is currently serving as the chairman of the Board as well as the chief executive officer of the Company. She has been primarily involved in developing overall corporate and business strategies of our Group and making significant business and operational decisions of our Group. Our Directors consider that vesting the roles of both the chairman of the Board and the chief executive officer of the Company in Ms. Chen is beneficial to the business prospects of the Group by ensuring consistent leadership to the Group as well as prompt and effective decision making and implementation. In addition, our Directors believe that this structure will not impair the balance of power and authority between the Board and the management of the Company, given that: (1) decision to be made by our Board requires approval by at least a majority of our Directors; (2) Ms. Chen and the other Directors are aware of and undertake to fulfil their fiduciary duties as Directors, which require, among other things, that she acts for the benefit and in the best interests of our Company and will make decisions for our Company accordingly; (3) the balance of power and authority is ensured by the operations of the Board, which consists of one executive Director, three non-executive Directors and three independent non-executive Directors, and has a fairly strong independence element; and (4) the overall strategic and other key business, financial, and operational policies of our Company are made collectively after thorough discussion at both Board, and senior management levels.

The Board shall nevertheless review the structure and composition of the Board from time to time in light of prevailing circumstances, to maintain a high standard of corporate governance practices of the Company.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS BY DIRECTORS

The Company has adopted the Model Code as set out in Appendix C3 to the Listing Rules as its own code of conduct regarding the transactions of securities of the Company by its Directors, supervisors and the relevant employees who would likely possess inside information of the Company. Specific enquiry has been made to all Directors and supervisors of the Company and all of them have confirmed that they have complied with the Model Code during the six months ended June 30, 2026.

AUDIT COMMITTEE

The Audit Committee comprises two independent non-executive Directors, namely Ms. Chan Ka Lai Vanessa (chairperson) and Mr. Zheng Yufeng, and one non-executive Director, namely Mr. Zhu Guanfu.

The Audit Committee has reviewed the unaudited interim financial information of the Group for the six months ended June 30, 2026 together with the Group's auditor, BDO China Shu Lun Pan Certified Public Accountants LLP, and have discussed with the management the accounting principles and practices adopted by the Group and its internal controls and financial reporting matters.

SCOPE OF WORK OF BDO CHINA SHU LUN PAN CERTIFIED PUBLIC ACCOUNTANTS LLP

The figures in respect of the Group's unaudited interim financial information and the related notes thereto for the six months ended June 30, 2026 as set out in the announcement have been reviewed by the Group's auditor, BDO China Shu Lun Pan Certified Public Accountants LLP.

INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2026 (six months ended June 30, 2025: nil).

PUBLICATION OF THE INTERIM RESULTS ANNOUNCEMENT AND THE INTERIM REPORT

This announcement was published on the website of the Stock Exchange (www.hkexnews.hk) and on the website of the Company (www.scientechmed.com). The interim report for the six months ended June 30, 2026 will be published on the websites of the Stock Exchange and the Company in due course.

DEFINITIONS

In this announcement, the following expressions have the meanings set out below unless the context requires otherwise:

"ASD"	atrial septal defect, a remnant opening, or a defect, between the left and right atria resulting from the abnormal development, absorption and fusion of the atrial septum during embryonic development
"Audit Committee"	the audit committee of the Board
"Board"	the board of Directors of the Company
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"CHD"	congenital heart disease, the formation of the heart and blood vessels during embryonic development or abnormal development or failure to close the channels that should be automatically closed after birth, resulting in abnormalities in the solid structure or function of the blood vessels in the heart or thoracic cavity
"Company"	LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司), a joint stock limited liability company established in the PRC on January 29, 2021 and whose Shares are listed on the Main Board of the Stock Exchange
"Director(s)"	the director(s) of the Company
"FIM"	First in man

"Global Offering"	has the meaning ascribed to it under the Prospectus
"Group", "we", "us", or "our"	the Company and its subsidiaries from time to time
"HK dollar" or "HK$"	Hong Kong dollars, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the PRC
"LAA"	left atrial appendage, a long, narrow and curved blind-end structure extending forward and downward along the anterior wall of the left atrium, which has active diastolic and secretory functions
"Lepu Medical"	Lepu Medical Technology (Beijing) Co., Ltd.# (樂普(北京)醫療器械股份有限公司), a company listed on the ChiNext Board of the Shenzhen Stock Exchange, stock code: 300003, one of our Controlling Shareholders
"Listing Date"	November 8, 2022, being the date on which the Shares of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.* (樂普心泰醫療科技(上海)股份有限公司) were listed on the Main Board of the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"Main Board"	the Main Board of the Stock Exchange
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers contained in Appendix C3 to the Listing Rules
"NMPA"	the National Medical Products Administration of the PRC (國家藥品監督管理局), formerly known as the China Food and Drug Administration
"PDA"	patent ductus arteriosus, a remnant opening of the ductus arteriosus, which fails to close normally in one year after birth
"PFO"	patent foramen ovale, a remnant opening of the fetal foramen ovale, which fails to close normally in one year after birth
"PRC" or "China"	the People's Republic of China, excluding, for the purposes of this announcement, Hong Kong Special Administrative Region, the Macau Special Administrative Region and Taiwan
"Prospectus"	the prospectus issued by the Company on October 27, 2022 in connection with the Hong Kong public offering of the Shares
"Reporting Period"	six months from January 1, 2026 to June 30, 2026
"RMB"	Renminbi, the lawful currency of the PRC
"Shareholder(s)"	holder(s) of Share(s)

"Shares"	ordinary share(s) in the share capital of the Company with a par value of RMB1.00 each
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"TAVR"	transcatheter aortic valve replacement, a catheter-based technique to implant a new aortic valve in a minimally invasive procedure that does not involve open-chest surgery to correct severe aortic stenosis
"US$" or "USD"	United States dollars, the lawful currency of the United States of America
"VSD"	ventricular septal defect, a defect, or a hole, in the septum between the left and right ventricles of the heart, which may lead to abnormal blood circulation and pulmonary hypertension and other complications in severe cases
"%"	per cent

By order of the Board
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.*
樂普心泰醫療科技(上海)股份有限公司
Chairman of the Board and Executive Director
Ms. Chen Juan

Shanghai, the People's Republic of China
August 21, 2026

As at the date of this announcement, the Board comprises Ms. Chen Juan as executive Director; Ms. Zhang Yuxin, Mr. Fu Shan and Mr. Zhu Guanfu as non-executive Directors; and Ms. Chan Ka Lai Vanessa, Mr. Zheng Yufeng, and Mr. Zheng Junwei as independent non-executive Directors.

* *The Company is a registered non-Hong Kong company as defined under the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) and it is registered under its Chinese name and under the English name "LEPU ScienTech Medical Technology (Shanghai) Co., Ltd.".*

For identification purposes only